Summit Partners Public Asset Management, LLC Intra Cellular Therapies, Inc. Transaction History

Summit Partners Public Asset Management, LLC

  • $2.79 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023
BUY
$54.67 - $66.44 $4.59 Million - $5.58 Million
83,926 Added 14248.9%
84,515 $5.35 Million
Q1 2023

May 15, 2023
BUY
$43.8 - $56.99 $25,798 - $33,567
589 New
589 $31,000
Q2 2022

Aug 15, 2022
SELL
$43.0 - $65.64 $4.37 Million - $6.67 Million
-101,572 Reduced 42.34%
138,331 $7.9 Million
Q1 2022

May 16, 2022
BUY
$38.74 - $62.09 $9.29 Million - $14.9 Million
239,903 New
239,903 $14.7 Million

Others Institutions Holding ITCI

# of Institutions
378
Shares Held
84.7M
Call Options Held
319K
Put Options Held
143K
View Full List

About Intra-Cellular Therapies, Inc.

ITCI Quotes by TradingView
  • Ticker ITCI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 94,401,696
  • Market Cap $7.85B
  • Description
  • Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...
More about ITCI
Track This Portfolio

Track Summit Partners Public Asset Management, LLC Portfolio

Follow Summit Partners Public Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Summit Partners Public Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Summit Partners Public Asset Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email